SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
Scynexis, Inc., a clinical-stage biotech focused on rare kidney disease and invasive fungal infections, reported a Q2 2026 net income of $7.4 million, versus a loss a year earlier, largely driven by a $14.2 million noncash gain from warrant liability revaluation. Operating performance remained negative, with Q2 license revenue from its GSK agreement at $0.2 million and an operating loss of $7.8 million.
For the first six months of 2026, Scynexis recorded a net loss of $13.9 million on $0.2 million in revenue, as it increased investment in its pipeline. Research and development expense rose to $16.2 million, including an $8.0 million in-process R&D charge tied to acquiring the SCY-770 AMPK activator program for Autosomal Dominant Polycystic Kidney Disease. SG&A expenses were $8.7 million.
Liquidity improved following a March 2026 private placement that generated $40.0 million gross and $36.9 million net proceeds. As of June 30 2026, cash, cash equivalents and investments totaled $71.1 million, with total assets of $75.0 million and stockholders’ equity of $66.9 million. Management states these resources are sufficient to fund ongoing operations for at least 12 months and believes they extend the runway into 2029. A one-for-eight reverse stock split and subsequent authorized share increase also helped regain and support Nasdaq listing compliance.
Federated Hermes, Inc. and related parties report holdings in SCYNEXIS, Inc. common stock. The group, including Federated Hermes, Inc., the Voting Shares Irrevocable Trust, and Thomas R., Ann C., and J. Christopher Donahue, reports beneficial ownership of 441,658 shares of SCYNEXIS common stock, representing 4.03% of the class as of June 30, 2026.
The Voting Shares Irrevocable Trust has sole voting and dispositive power over these shares. The individual Donahues report shared voting and dispositive power over the same 441,658 shares. All reporting persons state, pursuant to Rule 13d-4, that the filing should not be construed as an admission of beneficial ownership and expressly disclaim beneficial ownership of the securities held by the managed funds.
SCYNEXIS INC ownership update: Federated Hermes, Inc. and related parties report 55,207 shares of Common Stock, representing 4.45% of the class as shown on the cover pages. The filing is an amendment (No. 17) to a Schedule 13G/A and includes a Rule 13d-4 disclaimer regarding beneficial ownership.
SCYNEXIS INC director Brian Philippe Tinmouth received new equity awards. On June 26, 2026, he was granted 2,875 shares of Common Stock as a restricted stock unit award, with all shares vesting on the first anniversary of the grant if he continues serving as a non-employee director.
He was also granted a stock option for 2,875 shares of Common Stock at an exercise price of $3.85 per share, expiring on June 25, 2036, which likewise vests in full after one year of continued service. Following the grant, he directly holds 12,125 shares of Common Stock. The share amounts reflect a 1-for-8 reverse stock split effective on May 29, 2026.
Macdonald Guy reported acquisition or exercise transactions in this Form 4 filing.
SCYNEXIS director Guy Macdonald received equity compensation on June 26, 2026, consisting of 2,875 restricted stock units and a stock option for 2,875 shares of common stock at $3.85 per share. Both awards vest in full on the first anniversary of grant if he continues serving as a non-employee director. Following the grant, he directly holds 12,625 common shares. All share amounts reflect SCYNEXIS’s 1-for-8 reverse stock split effective May 29, 2026.
SCYNEXIS Inc director Armando Anido reported receiving equity-based compensation. He was granted 2,875 shares of Common Stock as restricted stock units and 2,875 stock options, both at no cost to him. The options have an exercise price of $3.85 per share and expire on June 25, 2036.
All 2,875 restricted stock units and the 2,875 options vest 100% on the first anniversary of the grant date, provided he continues serving as a non-employee director on that vesting date. After these grants, Anido directly holds 11,750 Common shares and 2,875 options. The share amounts reflect a 1-for-8 reverse stock split effective May 29, 2026.
SCYNEXIS director David C. Hastings received new equity awards as part of his compensation. He was granted 2,875 shares of common stock and a stock option for 2,875 shares at an exercise price of $3.85 per share. Both the restricted stock units and the option vest 100% on the first anniversary of the June 26, 2026 grant date, as long as he continues serving as a non-employee director. After the stock grant, he directly holds 11,522 common shares, and the new option expires on June 25, 2036. All amounts reflect a 1-for-8 reverse stock split effective May 29, 2026.
HANHAM ANN reported acquisition or exercise transactions in this Form 4 filing.
SCYNEXIS director Ann Hanham received new equity awards in the form of common stock and stock options. She was granted 2,875 shares of common stock at no cost and 2,875 stock options with a strike price of $3.85 per share. All 2,875 restricted stock units and all 2,875 options vest in full on the first anniversary of the grant date if she continues serving as a non-employee director. After the stock grant, she directly holds 11,577 shares of common stock.
SCYNEXIS, Inc. is registering the resale of up to 87,000,000 shares of common stock under an effective Form S-3, covering shares already held by selling stockholders and shares issuable from existing warrants.
The company also amended its certificate of incorporation to increase authorized stock from 23,750,000 to 65,000,000 shares, including an increase in authorized common stock from 18,750,000 to 60,000,000 shares. Stockholders approved this change at the June 25, 2026 annual meeting, held before a 1-for-8 reverse stock split that took effect on May 29, 2026. Certain warrants become exercisable following the authorized share increase, with pre-funded warrants priced at $0.0001 per share and common warrants at $1.20 per share, all on a pre-split basis.
SCYNEXIS, Inc. has approved and implemented a one-for-eight reverse stock split of its common stock, together with a reduction in authorized shares. Effective May 29, 2026, every eight issued and outstanding shares were combined into one share, and authorized common shares were reduced from 150,000,000 to 18,750,000 with no change in par value.
The reverse split applies proportionately to all stockholders and adjusts the share counts and, where applicable, exercise prices of stock options, restricted stock units and warrants. No fractional shares will be issued; holders entitled to fractions will receive cash instead. SCYNEXIS common stock is scheduled to begin trading on Nasdaq on a split-adjusted basis on June 1, 2026 under the symbol SCYX with a new CUSIP of 811292 309.